Tag: next-generation antibody therapeutics market analysis

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Next-Generation Antibody Therapeutics Market Expansion From $8.35 Billion In 2026 To $12.63 Billion In 2030

Anticipated to experience substantial expansion, the market for next-generation antibody therapeutics is projected to increase from $7.56 billion in 2025 to $8.35 billion by 2026, reflecting a compound annual growth rate of 10.4%. Key drivers behind this historical growth trajectory include a rise in the number of approved monoclonal antibodies, the escalating incidence of cancer, an enhancement in biologics production capabilities, increased financial commitment to pharmaceutical research and development, and the streamlining of regulatory processes for biologic substances.

The market for next-generation antibody therapeutics is poised for substantial expansion in the coming years, projected to reach $12.63 billion by 2030 with a compound annual growth rate (

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12678&type=smp

Next-Generation Antibody Therapeutics Market Demand Drivers: What Is Fueling Industry Growth?

The escalating incidence of chronic conditions is poised to be a significant catalyst for the expansion of the next-generation antibody therapeutics sector. These long-lasting health issues, persisting for a year or more and often requiring ongoing medical attention or limiting daily life, create a compelling need for advanced treatment options. Next-generation antibody therapeutics offer a targeted approach to managing these chronic illnesses, providing a mechanism to improve patient prognoses. Illustratively, data from the National Center for Biotechnology Information (NCBI) in January 2023 indicated that by 2050, the population aged 50 and above experiencing at least one chronic illness is anticipated to more than double, reaching 142.66 million. Consequently, the mounting burden of chronic diseases is directly fueling the advancement and adoption of next-generation antibody therapeutics.

Next-Generation Antibody Therapeutics Market Segment Breakdown: Which Categories Generate The Most Revenue?

The next-generation antibody therapeutics market covered in this report is segmented –

1) By Types Of Antibodies: Monoclonal Antibodies, Polyclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Types

2) By Therapeutic Area: Oncology, Autoimmune Diseases, Infectious Diseases, Neurodegenerative Disorders, Other Therapeutic Areas

3) By End-User: Hospitals And Clinics, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End-Users

Subsegments:

1) By Monoclonal Antibodies: IgG Monoclonal Antibodies, IgM Monoclonal Antibodies

2) By Polyclonal Antibodies: Serum-Derived Polyclonal Antibodies, Hybridoma-Derived Polyclonal Antibodies

3) By Bispecific Antibodies: Dual-Targeting Antibodies, Single-Chain Variable Fragment (scFv) Antibodies

4) By Antibody-Drug Conjugates (ADCs): Targeted ADCs, Payload Types

5) By Other Types: Nanobodies, Engineered Antibodies

Next-Generation Antibody Therapeutics Market Innovation Trends: Which Developments Are Transforming The Industry?

Key players in the next-generation antibody therapeutics sector are actively pursuing technological innovations, including their proprietary Molecular Indexing of Proteins by Self-Assembly (MIPSA) technology, to refine protein identification and characterization processes, thereby paving the way for more precise and efficacious therapies. These forward-thinking developments are designed to optimize therapeutic outcomes, decrease expenditure, and tackle intricate illnesses with heightened accuracy. The Molecular Indexing of Proteins by Self-Assembly (MIPSA) technology facilitates the systematic organization of protein molecules into ordered arrangements for superior analytical and quantitative capabilities, significantly boosting sensitivity and precision in protein detection for both research and diagnostic applications. Illustrating this trend, Infinity Bio, Inc., an American biotechnology firm, introduced a novel antibody profiling platform in January 2024, which leverages MIPSA technology to conduct high-volume, economical assessments of immune responses, with the ultimate goal of deepening comprehension of diseases and tailoring treatment approaches.

Next-Generation Antibody Therapeutics Market Key Players And Strategic Industry Positioning

Major companies operating in the next-generation antibody therapeutics market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Genentech Inc., Kyowa Hakko Kirin Co. Ltd., Seagen Inc., Seattle Genetics Inc., Xencor Inc., ImmunoGen Inc., Genmab A/S, Zymeworks Inc., NBE-Therapeutics AG, Daiichi Sankyo Company Limited, Merck & Co Inc., Novartis AG, AbCellera Biologics Inc., Sotio Biotech, F-Star Therapeutics Ltd., ADC Therapeutics SA, Harbour BioMed

Access The Complete Next-Generation Antibody Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/next-generation-antibody-therapeutics-global-market-report

Next-Generation Antibody Therapeutics Market Geographic Distribution And Regional Opportunities

North Americawas the largest region in the next-generation antibody therapeutics market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation antibody therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Increase In Market Value Is Predicted For The Next-Generation Antibody Therapeutics Market During The 2026–2030 Period?

The next-generation antibody therapeutics market has experienced rapid growth in recent years. It is anticipated to increase from $7.56 billion in 2025 to $8.35 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.4%. Historically, this expansion can be attributed to several factors, including an increase in monoclonal antibody approvals, the growing prevalence of cancer, the expansion of biologics manufacturing capacity, rising investment in pharmaceutical R&D, and improved regulatory pathways for biologics.

The next-generation antibody therapeutics market is anticipated to experience substantial growth in the upcoming years, projected to reach $12.63 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.9%. This expansion during the forecast period is driven by progress in antibody engineering technologies, a heightened demand for targeted therapies, the escalating prevalence of chronic and autoimmune diseases, the broadening of clinical trials into emerging markets, and increasing collaborations between biotechnology and pharmaceutical firms. Key trends anticipated during this period encompass the development of bispecific and multispecific antibody platforms, the rising uptake of antibody-drug conjugates in oncology, an intensified focus on high-affinity and long-acting antibodies, an expanding clinical pipeline for rare and orphan diseases, and a move towards personalized antibody-based therapies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12678&type=smp

What Primary Factors Are Fueling The Expansion Of The Next-Generation Antibody Therapeutics Market?

The rising occurrence of chronic illnesses is anticipated to boost the expansion of the next-generation antibody therapeutics market in the future. These are health conditions enduring a year or more, necessitating ongoing medical attention, limiting daily functions, or both. Next-generation antibody treatments offer a therapeutic role for chronic disease sufferers, providing more targeted interventions that improve patient outcomes. For instance, in January 2023, according to the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, it was projected that by the year 2050, the number of individuals aged 50 years and older who have at least one chronic illness will surge by 99.5%, rising to 142.66 million. Consequently, the growing incidence of chronic diseases is propelling the expansion of the next-generation antibody therapeutics market.

How Is The Next-Generation Antibody Therapeutics Market Distributed Across Key Segments?

The next-generation antibody therapeutics market covered in this report is segmented –

1) By Types Of Antibodies: Monoclonal Antibodies, Polyclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Types

2) By Therapeutic Area: Oncology, Autoimmune Diseases, Infectious Diseases, Neurodegenerative Disorders, Other Therapeutic Areas

3) By End-User: Hospitals And Clinics, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End-Users

Subsegments:

1) By Monoclonal Antibodies: IgG Monoclonal Antibodies, IgM Monoclonal Antibodies

2) By Polyclonal Antibodies: Serum-Derived Polyclonal Antibodies, Hybridoma-Derived Polyclonal Antibodies

3) By Bispecific Antibodies: Dual-Targeting Antibodies, Single-Chain Variable Fragment (scFv) Antibodies

4) By Antibody-Drug Conjugates (ADCs): Targeted ADCs, Payload Types

5) By Other Types: Nanobodies, Engineered Antibodies

What Trends Are Shaping The Next-Generation Antibody Therapeutics Market Structure?

Leading companies in the next-generation sequencing (NGS) sample preparation market are increasingly focusing on automating sample preparation, employing technologies such as digital microfluidics platforms. This strategic shift aims to improve efficiency, lessen manual errors, and streamline sample processing to achieve more precise and timely genomic analysis. Digital microfluidics platforms are advanced systems that manipulate small volumes of fluids on a microchip using electrical fields, facilitating accurate and automated handling of samples for applications like NGS sample preparation. For example, in September 2023, INTEGRA Biosciences, a Switzerland-based provider of intuitive solutions for liquid handling and media preparation, introduced the MIRO CANVAS. This compact digital microfluidics platform is designed for fully automated next-generation sequencing (NGS) sample preparation. This innovative system enhances both accuracy and efficiency by automating workflows, reducing the required hands-on time to just 15 minutes per run, and enabling immediate processing of clinical specimens. The MIRO CANVAS seeks to simplify NGS procedures and support advanced genomics research by preserving DNA integrity and minimizing reagent usage.

Who Are The Leading Firms Participating In The Next-Generation Antibody Therapeutics Market?

Major companies operating in the next-generation antibody therapeutics market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Genentech Inc., Kyowa Hakko Kirin Co. Ltd., Seagen Inc., Seattle Genetics Inc., Xencor Inc., ImmunoGen Inc., Genmab A/S, Zymeworks Inc., NBE-Therapeutics AG, Daiichi Sankyo Company Limited, Merck & Co Inc., Novartis AG, AbCellera Biologics Inc., Sotio Biotech, F-Star Therapeutics Ltd., ADC Therapeutics SA, Harbour BioMed

Access The Complete Next-Generation Antibody Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/next-generation-antibody-therapeutics-global-market-report

Which Region Commands The Largest Share Of The Next-Generation Antibody Therapeutics Market?

North America was the largest region in the next-generation antibody therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation antibody therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Next-Generation Antibody Therapeutics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=12678&type=smp

Browse Through More Reports Similar to the Global Next-Generation Antibody Therapeutics Market 2026, By The Business Research Company

Next Generation Sequencing Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/next-generation-sequencing-global-market-report

Next Generation Military Power Supply Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/next-generation-military-power-supply-global-market-report

Next Generation Computing Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/next-generation-computing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Next-Generation Antibody Therapeutics Market Grow Between 2026 And 2030?

The next-generation antibody therapeutics market size has experienced rapid growth in recent years. It is projected to expand from $7.56 billion in 2025 to $8.35 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.4%. The increase observed in the historic period can be attributed to factors such as a rise in monoclonal antibody approvals, the growing prevalence of cancer, an expansion of biologics manufacturing capacity, increased investment in pharmaceutical research and development, and enhanced regulatory pathways for biologics.

The next-generation antibody therapeutics market is projected for significant expansion over the coming years. By 2030, this market is anticipated to reach $12.63 billion, exhibiting a compound annual growth rate (CAGR) of 10.9%. Several factors will contribute to this projected increase, including innovations in antibody engineering technologies, a growing need for targeted treatments, the rising occurrence of chronic and autoimmune conditions, the expansion of clinical research in developing regions, and increasing collaborations between biotechnology and pharmaceutical firms. Key trends anticipated during this period involve the broadening of bispecific and multispecific antibody platforms, the increased use of antibody-drug conjugates in cancer treatment, a heightened emphasis on high-affinity and extended-duration antibodies, an expanding pipeline of clinical trials for rare and orphan diseases, and a move towards customized antibody-based therapeutic approaches.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12678&type=smp

Which Key Drivers Are Affecting The Next-Generation Antibody Therapeutics Market Development?

The rising occurrence of chronic ailments is anticipated to fuel the expansion of the next-generation antibody therapeutics market. These are conditions persisting for a year or more, necessitating ongoing medical attention, limiting daily functions, or a combination thereof. Next-generation antibody therapeutics offer a therapeutic role for individuals with chronic illnesses, delivering more focused care which benefits patient outcomes. For instance, in January 2023, according to the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, it was projected that by the year 2050, the number of individuals aged 50 years and older who have at least one chronic illness will surge by 99.5%, rising to 142.66 million. Consequently, the increasing prevalence of chronic diseases is propelling the growth of the next-generation antibody therapeutics market.

How Is The Next-Generation Antibody Therapeutics Market Segmented Across Different Segment Categories?

The next-generation antibody therapeutics market covered in this report is segmented –

1) By Types Of Antibodies: Monoclonal Antibodies, Polyclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Types

2) By Therapeutic Area: Oncology, Autoimmune Diseases, Infectious Diseases, Neurodegenerative Disorders, Other Therapeutic Areas

3) By End-User: Hospitals And Clinics, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End-Users

Subsegments:

1) By Monoclonal Antibodies: IgG Monoclonal Antibodies, IgM Monoclonal Antibodies

2) By Polyclonal Antibodies: Serum-Derived Polyclonal Antibodies, Hybridoma-Derived Polyclonal Antibodies

3) By Bispecific Antibodies: Dual-Targeting Antibodies, Single-Chain Variable Fragment (scFv) Antibodies

4) By Antibody-Drug Conjugates (ADCs): Targeted ADCs, Payload Types

5) By Other Types: Nanobodies, Engineered Antibodies

What Trends Are Transforming The Next-Generation Antibody Therapeutics Market?

Major companies within the next-generation antibody therapeutics market are concentrating on creating technological breakthroughs, such as the proprietary Molecular Indexing of Proteins by Self-Assembly (MIPSA) technology, to improve protein identification and characterization, which in turn leads to more focused and efficient treatments. These advancements are designed to enhance therapeutic outcomes, decrease expenses, and address intricate diseases with greater accuracy. Molecular Indexing of Proteins by Self-Assembly (MIPSA) is a method that organizes protein molecules into structured arrangements for more effective analysis and quantification. It boosts the sensitivity and precision of protein detection, proving valuable in research and diagnostic fields. For example, in January 2024, Infinity Bio, Inc., a US-based biotechnology company, released a next-generation antibody profiling platform that employs MIPSA technology for rapid, cost-effective analysis of immune responses, intending to deepen disease understanding and customize treatment strategies.

Which Organizations Play A Role In The Next-Generation Antibody Therapeutics Market Landscape?

Major companies operating in the next-generation antibody therapeutics market are Pfizer Inc., F. Hoffmann‑La Roche Ltd., Bristol‑Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Genentech Inc., Kyowa Hakko Kirin Co. Ltd., Seagen Inc., Seattle Genetics Inc., Xencor Inc., ImmunoGen Inc., Genmab A/S, Zymeworks Inc., NBE‑Therapeutics AG, Daiichi Sankyo Company Limited, Merck & Co Inc., Novartis AG, AbCellera Biologics Inc., Sotio Biotech, F‑Star Therapeutics Ltd., ADC Therapeutics SA, Harbour BioMed

Get The Full Next-Generation Antibody Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/next-generation-antibody-therapeutics-global-market-report

Which Region Is The Largest In The Next-Generation Antibody Therapeutics Market?

North America was the largest region in the next-generation antibody therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation antibody therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Next-Generation Antibody Therapeutics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/next-generation-antibody-therapeutics-global-market-report

Browse Through More Reports Similar to the Global Next-Generation Antibody Therapeutics Market 2026, By The Business Research Company

Next Generation Sequencing Market Report 2026

https://www.thebusinessresearchcompany.com/report/next-generation-sequencing-global-market-report

Next Generation Military Power Supply Market Report

https://www.thebusinessresearchcompany.com/report/next-generation-military-power-supply-global-market-report

Next Generation Computing Market Report

https://www.thebusinessresearchcompany.com/report/next-generation-computing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Next-Generation Antibody Therapeutics Market In 2026 And What Value Is Projected For 2030?

The next-generation antibody therapeutics market size has experienced swift expansion in recent years. It is anticipated to grow from $7.56 billion in 2025 to $8.35 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.4%. The market’s growth during the past period can be linked to an increase in monoclonal antibody approvals, the rising occurrence of cancer, the broadening of biologics manufacturing capacity, higher investment in pharmaceutical R&D, and refined regulatory pathways for biologics.

The next-generation antibody therapeutics market size is projected to experience swift expansion over the coming years. This market is anticipated to reach $12.63 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.9%. Factors contributing to this growth during the projection period include progress in antibody engineering technologies, an escalating need for targeted treatments, the growing occurrence of chronic and autoimmune conditions, the broadening of clinical trials in developing regions, and increasing collaborations between biotechnology and pharmaceutical firms. Key developments foreseen in this period encompass the broadening of bispecific and multispecific antibody platforms, a rising uptake of antibody-drug conjugates in cancer treatment, heightened attention on antibodies with high affinity and extended action, an expanding clinical pipeline for rare and orphan diseases, and a move towards personalized antibody-based therapeutic approaches.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12678&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Next-Generation Antibody Therapeutics Market?

The rising occurrence of chronic ailments is anticipated to drive expansion in the next-generation antibody therapeutics market in the future. These enduring health conditions persist for a year or more, requiring ongoing medical attention, limiting daily routines, or a combination of both factors. For individuals grappling with chronic illnesses, next-generation antibody therapeutics offer a therapeutic role by providing more targeted treatment, thereby improving patient outcomes. For example, data from January 2023, published by the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, indicated a forecast that by 2050, the population of individuals aged 50 years and older living with at least one chronic illness is set to increase by 99.5%, reaching 142.66 million. Consequently, the expanding prevalence of chronic diseases is fueling the growth of the next-generation antibody therapeutics market.

What Are The Key Segments Of The Next-Generation Antibody Therapeutics Market?

The next-generation antibody therapeutics market covered in this report is segmented –

1) By Types Of Antibodies: Monoclonal Antibodies, Polyclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Types

2) By Therapeutic Area: Oncology, Autoimmune Diseases, Infectious Diseases, Neurodegenerative Disorders, Other Therapeutic Areas

3) By End-User: Hospitals And Clinics, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End-Users

Subsegments:

1) By Monoclonal Antibodies: IgG Monoclonal Antibodies, IgM Monoclonal Antibodies

2) By Polyclonal Antibodies: Serum-Derived Polyclonal Antibodies, Hybridoma-Derived Polyclonal Antibodies

3) By Bispecific Antibodies: Dual-Targeting Antibodies, Single-Chain Variable Fragment (scFv) Antibodies

4) By Antibody-Drug Conjugates (ADCs): Targeted ADCs, Payload Types

5) By Other Types: Nanobodies, Engineered Antibodies

Which Trends Are Shaping The Future Of The Next-Generation Antibody Therapeutics Market?

Leading companies within the next-generation antibody therapeutics market are prioritizing the development of technological breakthroughs, exemplified by their proprietary Molecular Indexing of Proteins by Self-Assembly (MIPSA) technology. The goal is to improve protein identification and characterization, ultimately leading to more precise and impactful treatments. These advancements are designed to enhance therapeutic profiles, decrease expenditures, and tackle intricate diseases with superior accuracy. Molecular Indexing of Proteins by Self-Assembly (MIPSA) functions by arranging protein molecules into structured assemblies, which allows for more effective analysis and quantification. This approach significantly boosts the sensitivity and accuracy of protein detection, making it highly beneficial for research and diagnostic purposes. For example, in January 2024, Infinity Bio, Inc., a US-based biotechnology company, unveiled a new antibody profiling platform. This platform leverages MIPSA technology for efficient and cost-effective analysis of immune responses, intending to foster a deeper understanding of diseases and enable more personalized treatment strategies.

Who Are The Leading Companies Operating In The Next-Generation Antibody Therapeutics Market?

Major companies operating in the next-generation antibody therapeutics market are Pfizer Inc., F. Hoffmann‑La Roche Ltd., Bristol‑Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Genentech Inc., Kyowa Hakko Kirin Co. Ltd., Seagen Inc., Seattle Genetics Inc., Xencor Inc., ImmunoGen Inc., Genmab A/S, Zymeworks Inc., NBE‑Therapeutics AG, Daiichi Sankyo Company Limited, Merck & Co Inc., Novartis AG, AbCellera Biologics Inc., Sotio Biotech, F‑Star Therapeutics Ltd., ADC Therapeutics SA, Harbour BioMed

Read the full next-generation antibody therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/next-generation-antibody-therapeutics-global-market-report

What Are The Leading Geographic Regions In The Next-Generation Antibody Therapeutics Market?

North America was the largest region in the next-generation antibody therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation antibody therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Next-Generation Antibody Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12678&type=smp

Browse Through More Reports Similar to the Global Next-Generation Antibody Therapeutics Market 2026, By The Business Research Company

Next Generation Sequencing Global Market Report

https://www.thebusinessresearchcompany.com/report/next-generation-sequencing-global-market-report

Next Generation Military Power Supply Global Market Report

https://www.thebusinessresearchcompany.com/report/next-generation-military-power-supply-global-market-report

Next Generation Computing Global Market Report

https://www.thebusinessresearchcompany.com/report/next-generation-computing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the next-generation antibody therapeutics market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Next-Generation Antibody Therapeutics Market be in 2030 compared with 2026?

The market for next-generation antibody therapeutics has observed rapid expansion in recent years. It is anticipated to increase from $7.56 billion in 2025 to $8.35 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.4%. The historical surge in this market can be linked to factors such as an uptick in monoclonal antibody approvals, a rise in cancer cases, the enlargement of biologics manufacturing capabilities, greater investment in pharmaceutical R&D, and more streamlined regulatory processes for biologics.

The next-generation antibody therapeutics market size is anticipated to experience swift expansion in the coming years, with projections indicating a growth to $12.63 billion by 2030, achieving a compound annual growth rate (CAGR) of 10.9%. This upward trend over the forecast period is propelled by advancements in antibody engineering technologies, an increasing need for targeted therapies, the rising occurrence of chronic and autoimmune diseases, the expansion of clinical trials within emerging markets, and growing collaborations between biotech and pharmaceutical companies. Significant developments expected during this timeframe involve the broadening of bispecific and multispecific antibody platforms, the increasing utilization of antibody-drug conjugates in oncology, a heightened emphasis on high-affinity and long-acting antibodies, a burgeoning clinical pipeline for rare and orphan diseases, and a noticeable shift toward personalized antibody-based treatments.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12678&type=smp

What Drivers Are Guiding Growth Patterns In The Next-Generation Antibody Therapeutics Market?

The escalating incidence of chronic ailments is anticipated to fuel the expansion of the next-generation antibody therapeutics market in the future. These conditions are defined as health issues persisting for at least a year, requiring ongoing medical intervention, limiting daily functions, or a combination of these factors. Next-generation antibody therapeutics offer a treatment approach for individuals suffering from chronic illnesses, providing more targeted care and thereby improving patient outcomes. As an illustration, data from January 2023, released by the National Center for Biotechnology Information (NCBI), a US National Library of Medicine, indicated a forecast that by 2050, the population aged 50 years and older afflicted with at least one chronic condition is expected to increase by 99.5%, reaching 142.66 million. Consequently, the rising occurrence of chronic diseases is a key factor propelling the expansion of the next-generation antibody therapeutics market.

How Is The Next-Generation Antibody Therapeutics Market Divided Into Segments?

The next-generation antibody therapeutics market covered in this report is segmented –

1) By Types Of Antibodies: Monoclonal Antibodies, Polyclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Types

2) By Therapeutic Area: Oncology, Autoimmune Diseases, Infectious Diseases, Neurodegenerative Disorders, Other Therapeutic Areas

3) By End-User: Hospitals And Clinics, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End-Users

Subsegments:

1) By Monoclonal Antibodies: IgG Monoclonal Antibodies, IgM Monoclonal Antibodies

2) By Polyclonal Antibodies: Serum-Derived Polyclonal Antibodies, Hybridoma-Derived Polyclonal Antibodies

3) By Bispecific Antibodies: Dual-Targeting Antibodies, Single-Chain Variable Fragment (scFv) Antibodies

4) By Antibody-Drug Conjugates (ADCs): Targeted ADCs, Payload Types

5) By Other Types: Nanobodies, Engineered Antibodies

Which Trends Are Guiding The Evolution Of The Next-Generation Antibody Therapeutics Market?

Leading companies within the next-generation antibody therapeutics market are concentrating on developing technological advancements, such as their proprietary Molecular Indexing of Proteins by Self-Assembly (MIPSA) technology, to improve protein identification and characterization, thereby enabling more targeted and effective treatments. These innovations are consequently designed to enhance therapeutic profiles, reduce costs, and address complex diseases with greater precision. Molecular Indexing of Proteins by Self-Assembly (MIPSA) is a method that organizes protein molecules into structured assemblies, allowing for improved analysis and quantification. This approach increases sensitivity and accuracy in detecting proteins, which is valuable in both research and diagnostics. For example, in January 2024, Infinity Bio, Inc., a US-based biotechnology company, introduced a next-generation antibody profiling platform that leverages MIPSA technology for high-throughput, cost-effective analysis of immune responses, with the goal of deepening disease understanding and personalizing treatment strategies.

Which Leading Companies Dominate The Next-Generation Antibody Therapeutics Market Share?

Major companies operating in the next-generation antibody therapeutics market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Genentech Inc., Kyowa Hakko Kirin Co. Ltd., Seagen Inc., Seattle Genetics Inc., Xencor Inc., ImmunoGen Inc., Genmab A/S, Zymeworks Inc., NBE-Therapeutics AG, Daiichi Sankyo Company Limited, Merck & Co Inc., Novartis AG, AbCellera Biologics Inc., Sotio Biotech, F-Star Therapeutics Ltd., ADC Therapeutics SA, Harbour BioMed

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/next-generation-antibody-therapeutics-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Next-Generation Antibody Therapeutics Market?

North America was the largest region in the next-generation antibody therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation antibody therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Next-Generation Antibody Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12678&type=smp

Browse Through More Reports Similar to the Global Next-Generation Antibody Therapeutics Market 2026, By The Business Research Company

Monoclonal Antibodies Market Report 2026

https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report

Antibody Discovery Market Report 2026

https://www.thebusinessresearchcompany.com/report/antibody-discovery-global-market-report

Antibody Drug Conjugates Market Report 2026

https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model